These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 38834388)

  • 1. Recommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer in 2024: a report from the ESMO Precision Medicine Working Group.
    Mosele MF; Westphalen CB; Stenzinger A; Barlesi F; Bayle A; Bièche I; Bonastre J; Castro E; Dienstmann R; Krämer A; Czarnecka AM; Meric-Bernstam F; Michiels S; Miller R; Normanno N; Reis-Filho J; Remon J; Robson M; Rouleau E; Scarpa A; Serrano C; Mateo J; André F
    Ann Oncol; 2024 Jul; 35(7):588-606. PubMed ID: 38834388
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group.
    Mosele F; Remon J; Mateo J; Westphalen CB; Barlesi F; Lolkema MP; Normanno N; Scarpa A; Robson M; Meric-Bernstam F; Wagle N; Stenzinger A; Bonastre J; Bayle A; Michiels S; Bièche I; Rouleau E; Jezdic S; Douillard JY; Reis-Filho JS; Dienstmann R; André F
    Ann Oncol; 2020 Nov; 31(11):1491-1505. PubMed ID: 32853681
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT).
    Mateo J; Chakravarty D; Dienstmann R; Jezdic S; Gonzalez-Perez A; Lopez-Bigas N; Ng CKY; Bedard PL; Tortora G; Douillard JY; Van Allen EM; Schultz N; Swanton C; André F; Pusztai L
    Ann Oncol; 2018 Sep; 29(9):1895-1902. PubMed ID: 30137196
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recommendations for the Use of Next-Generation Sequencing and the Molecular Tumor Board for Patients with Advanced Cancer: A Report from KSMO and KCSG Precision Medicine Networking Group.
    Yoon S; Kim M; Hong YS; Kim HS; Kim ST; Kim J; Yun H; Yoo C; Ahn HK; Kim HS; Lee IH; Kim IH; Park I; Jeong JH; Cheon J; Kim JW; Yun J; Lim SM; Cha Y; Jang SJ; Zang DY; Kim TW; Kang JH; Kim JH
    Cancer Res Treat; 2022 Jan; 54(1):1-9. PubMed ID: 34902959
    [TBL] [Abstract][Full Text] [Related]  

  • 5. How to read a next-generation sequencing report-what oncologists need to know.
    Schmid S; Jochum W; Padberg B; Demmer I; Mertz KD; Joerger M; Britschgi C; Matter MS; Rothschild SI; Omlin A
    ESMO Open; 2022 Oct; 7(5):100570. PubMed ID: 36183443
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recommendations for the use of next-generation sequencing in patients with metastatic cancer in the Asia-Pacific region: a report from the APODDC working group.
    Loong HH; Shimizu T; Prawira A; Tan AC; Tran B; Day D; Tan DSP; Ting FIL; Chiu JW; Hui M; Wilson MK; Prasongsook N; Koyama T; Reungwetwattana T; Tan TJ; Heong V; Voon PJ; Park S; Tan IB; Chan SL; Tan DSW
    ESMO Open; 2023 Aug; 8(4):101586. PubMed ID: 37356359
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Next-Generation Sequencing for Advanced Breast Cancer: What the Way to Go?
    Trapani D; Crimini E; Sandoval J; Curigliano G
    Cancer Treat Res; 2023; 188():343-351. PubMed ID: 38175352
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular tests and target therapies in oncology: recommendations from the Italian workshop.
    Pinto C; Biffoni M; Popoli P; Marchetti A; Marchetti P; Martini N; Normanno N
    Future Oncol; 2021 Sep; 17(26):3529-3539. PubMed ID: 34254524
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Implementing the European Society for Medical Oncology Scale for Clinical Actionability of Molecular Targets in a Comprehensive Profiling Program: Impact on Precision Medicine Oncology.
    Martin-Romano P; Mezquita L; Hollebecque A; Lacroix L; Rouleau E; Gazzah A; Bahleda R; Planchard D; Varga A; Baldini C; Postel-Vinay S; Friboulet L; Loriot Y; Verlingue L; Geraud A; Camus MN; Nicotra C; Soria JC; André F; Besse B; Massard C; Italiano A
    JCO Precis Oncol; 2022 Oct; 6():e2100484. PubMed ID: 36315916
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach.
    Luchini C; Bibeau F; Ligtenberg MJL; Singh N; Nottegar A; Bosse T; Miller R; Riaz N; Douillard JY; Andre F; Scarpa A
    Ann Oncol; 2019 Aug; 30(8):1232-1243. PubMed ID: 31056702
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Supporting Biomarker-Driven Therapies in Oncology: A Genomic Testing Cost Calculator.
    Stenzinger A; Cuffel B; Paracha N; Vail E; Garcia-Foncillas J; Goodman C; Lassen U; Vassal G; Sullivan SD
    Oncologist; 2023 May; 28(5):e242-e253. PubMed ID: 36961477
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Germline-focussed analysis of tumour-only sequencing: recommendations from the ESMO Precision Medicine Working Group.
    Mandelker D; Donoghue M; Talukdar S; Bandlamudi C; Srinivasan P; Vivek M; Jezdic S; Hanson H; Snape K; Kulkarni A; Hawkes L; Douillard JY; Wallace SE; Rial-Sebbag E; Meric-Bersntam F; George A; Chubb D; Loveday C; Ladanyi M; Berger MF; Taylor BS; Turnbull C
    Ann Oncol; 2019 Aug; 30(8):1221-1231. PubMed ID: 31050713
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Routine application of next-generation sequencing testing in uro-oncology-Are we ready for the next step of personalised medicine?
    Rodler S; Jung A; Greif PA; Rühlmann K; Apfelbeck M; Tamalunas A; Kretschmer A; Schulz GB; Szabados B; Stief C; Heinemann V; Westphalen CB; Casuscelli J
    Eur J Cancer; 2021 Mar; 146():1-10. PubMed ID: 33535139
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ESMO recommendations on the standard methods to detect NTRK fusions in daily practice and clinical research.
    Marchiò C; Scaltriti M; Ladanyi M; Iafrate AJ; Bibeau F; Dietel M; Hechtman JF; Troiani T; López-Rios F; Douillard JY; Andrè F; Reis-Filho JS
    Ann Oncol; 2019 Sep; 30(9):1417-1427. PubMed ID: 31268127
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment recommendations to cancer patients in the context of FDA guidance for next generation sequencing.
    Dy GK; Nesline MK; Papanicolau-Sengos A; DePietro P; LeVea CM; Early A; Chen H; Grand'Maison A; Boland P; Ernstoff MS; Edge S; Akers S; Opyrchal M; Chatta G; Odunsi K; Pabla S; Conroy JM; Glenn ST; DeFedericis HT; Burgher B; Andreas J; Giamo V; Qin M; Wang Y; Kanehira K; Lenzo FL; Frederick P; Lele S; Galluzzi L; Kuvshinoff B; Morrison C
    BMC Med Inform Decis Mak; 2019 Jan; 19(1):14. PubMed ID: 30658646
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The European Society for Medical Oncology (ESMO) Precision Medicine Glossary.
    Yates LR; Seoane J; Le Tourneau C; Siu LL; Marais R; Michiels S; Soria JC; Campbell P; Normanno N; Scarpa A; Reis-Filho JS; Rodon J; Swanton C; Andre F
    Ann Oncol; 2018 Jan; 29(1):30-35. PubMed ID: 29140430
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Usefulness and real-world outcomes of next generation sequencing testing in patients with cancer: an observational study on the impact of selection based on clinical judgement.
    Colomer R; Miranda J; Romero-Laorden N; Hornedo J; González-Cortijo L; Mouron S; Bueno MJ; Mondéjar R; Quintela-Fandino M
    EClinicalMedicine; 2023 Jun; 60():102029. PubMed ID: 37304496
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ESMO study on the availability and accessibility of biomolecular technologies in oncology in Europe.
    Bayle A; Bonastre J; Chaltiel D; Latino N; Rouleau E; Peters S; Galotti M; Bricalli G; Besse B; Giuliani R
    Ann Oncol; 2023 Oct; 34(10):934-945. PubMed ID: 37406812
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genomically matched therapy in refractory colorectal cancer according to ESMO Scale for Clinical Actionability of Molecular Targets: experience of a comprehensive cancer centre network.
    Mulet Margalef N; Castillo C; Mosteiro M; Pérez X; Aguilar S; Ruíz-Pace F; Gil M; Cuadra C; Ruffinelli JC; Martínez M; Losa F; Soler G; Teulé À; Castany R; Gallego R; Ruíz A; Garralda E; Élez E; Vivancos A; Tabernero J; Salazar R; Dienstmann R; Santos Vivas C
    Mol Oncol; 2023 Sep; 17(9):1908-1916. PubMed ID: 37097008
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of precision cancer medicine-current challenges in the use of next generation sequencing for comprehensive tumour genomic profiling and the role of clinical utility frameworks (Review).
    Christofyllakis K; Bittenbring JT; Thurner L; Ahlgrimm M; Stilgenbauer S; Bewarder M; Kaddu-Mulindwa D
    Mol Clin Oncol; 2022 Jan; 16(1):21. PubMed ID: 34909199
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.